DOYLE MITTIE (Chief Medical Officer) sold 15.8% of their position (679.00 shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $10.9K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/3/2026ACC: 0001918845-26-000006
Officer· Chief Medical Officer
Since Feb 2026
-679.00
Net shares
Net seller
$10.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
679.00 acquired · 1.36K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+679.00
Price / share
$8.04
Trade value
$5.46K
% of position
18.7%
4/1/2026
3.62K→4.30K
Common Stock
Direct
Shares
−679.00
Price / share
$16.00
Trade value
$10.86K
% of position
15.8%
4/1/2026
4.30K→3.62K
Total
Net shares
+0.00
Net value
-$5.40K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/1/2026 | M · Option Exercise | +679.00 | $8.04 | $5.46K | 18.7% | 3.62K | 4.30K |
| Common Stock Direct | 4/1/2026 | S · Sale | −679.00 | $16.00 | $10.86K | 15.8% | 4.30K | 3.62K |
| Total | +0.00 | -$5.40K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
679.00 shares
Shares
−679.00
Strike price
8.04
Held after
148.33K
Exercisable
—
4/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock679.00 shares | 4/1/2026 | M · Option Exercise | −679.00 | 8.04 | — | 148.33K |